A new alternative therapy in dermatology: tocilizumab

References

• Ding C, Jones G. Technology evaluation: MRA, Chuga. Curr Opin Mol Ther 2003;5:64–69
   PubMed Web of Science ®Google Scholar
• Smolen JS, Beaulieu A, Rubbert-Roth A, et al. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial. Lancet 2008;371:987–997
   PubMed Web of Science ®Google Scholar
• Coyle K. Clinical review: tocilizumab (Actemra). Food and Drug Administration; 2011. sBLA 12576/22
   Google Scholar
• Tanaka T, Kishimoto T. Targeting interleukin-6: all the way to treat autoimmune and inflammatory diseases. Int J Biol Sci 2012;8:1227–1236
   PubMed Web of Science ®Google Scholar
• Hashizume M, Mihara M. The roles of interleukin-6 in the pathogenesis of rheumatoid arthritis. Arthritis 2011;2011:765624
   PubMedGoogle Scholar
• Ash Z, Emery P. The role of tocilizumab in the management of rheumatoid arthritis. Expert Opin Biol Ther 2012;12:1277–1289
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Terao K, Mima T, et al. Mechanisms and pathologic significances in increase in serum interleukin-6, (IL-6): and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood 2008;112:3959–3964
   PubMed Web of Science ®Google Scholar
• Younis S, Rimar D, Slobodin G, et al. Tumor necrosis factor-associated palmoplantar pustular psoriasis treated with interleukin 6 blocker. J Rheumatol 2012;39:2055–2056
   PubMed Web of Science ®Google Scholar
• Saggini A, Chimenti S, Chiricozzi A. IL-6 as a druggable target in psoriasis: focus on pustular variants. J Immunol Res 2014;2014:964069
   PubMed Web of Science ®Google Scholar
• Jayasekera P, Parslew R, Al-Sharqi A. A case of tumour necrosis factor alpha inhibitor and rituximab induced plantar pustular psoriasis which completely resolved with tocilizumab. Br J Dermatol 2014;171:1546–1549
   PubMed Web of Science ®Google Scholar
• Rueda-Gotor J, González-Gay MA, Blanco Alonso R, et al. Successful effect of tocilizumab in anti-TNF-alpha-induced palmoplantar pustulosis in rheumatoid arthritis. Joint Bone Spine 2012;79:510–513
   PubMed Web of Science ®Google Scholar
• Palmou-Fontana N, Sánchez Gaviño JA, McGonagle D, et al. Tocilizumab-induced psoriasiform rash in rheumatoid arthritis. Dermatology 2014;228:311–313
   PubMed Web of Science ®Google Scholar
• Wendling D, Letho-Gyselinck H, Guillot X, et al. Psoriasis onset with tocilizumab treatment for rheumatoid arthritis. J Rheumatol 2012;39:657
   PubMed Web of Science ®Google Scholar
• Sparsa L, Afif N, Bularca S, et al. Paradoxical cutaneous reactions associated with tocilizumab therapy. Rev Med Interne 2014;35:613–616
   PubMed Web of Science ®Google Scholar
• Laurent S, Le Parc JM, Clérici T, et al. Onset of psoriasis following treatment with tocilizumab. Br J Dermatol 2010;163:1364–1365
   PubMed Web of Science ®Google Scholar
• Grasland A, Mahé E, Raynaud E, et al. Psoriasis onset with tocilizumab. Joint Bone Spine 2013;80:541–542
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Synovial effusion and synovial fluid biomarkers in psoriatic arthritis to assess intraarticular tumor necrosis factor-alpha blockade in the knee joint. Arthritis Res Ther 2010;12:R148
   PubMed Web of Science ®Google Scholar
• Fiocco U, Sfriso P, Oliviero F, et al. Molecular pathways involved in synovial cell inflammation and tumoral proliferation in diffuse pigmented villo, nodular synovitis. Autoimmun Rev 2010;9:780–784
   PubMed Web of Science ®Google Scholar
• Costa L, Caso F, Cantarini L, et al. Efficacy of tocilizumab in a patient with refractory psoriatic arthritis. Clin Rheumatol 2014;33:1355–1357
   PubMed Web of Science ®Google Scholar
• Ogata A, Kumanogoh A, Tanaka T. Pathological role of interleukin-6 in psoriatic arthritis. Arthritis 2012;2012:713618
   PubMedGoogle Scholar
• Hughes M, Chinoy H. Successful use of tocilizumab in a patient with psoriatic arthritis. Rheumatology (Oxford) 2013;52:1728–1729
   PubMed Web of Science ®Google Scholar
• Ogata A, Kumanogoh A, Tanaka T. Psoriatic arthritis in two patients with an inadequate response to treatment with tocilizumab. Joint Bone Spine 2012;79:85–87
   PubMed Web of Science ®Google Scholar
• Akman-Demir G, Tüzün E, Içöz S, et al. Interleukin-6 in neuro-Behcet's disease: association with disease subsets and long-term outcome. Cytokine 2008;44:373–376
   PubMed Web of Science ®Google Scholar
• Urbaniak P, Hasler P, Kretzschmar S. Refractory neuro-Behcet treated by tocilizumab: a case report. Clin Exp Rheumatol 2012;30(3 Suppl 72):73–75
   PubMed Web of Science ®Google Scholar
• Hirano T, Ohguro N, Hohki S, et al. A case of Behcet's disease treated with a humanized anti-interleukin-6 receptor antibody, tocilizumab. Mod Rheumatol 2012;22:298–302
   PubMed Web of Science ®Google Scholar
• Caso F, Laccarino L, Bettio S, et al. Refractory pemphigus foliaceus and Behcet's disease successfully treated with tocilizumab. Immunol Res 2013;56:390–397
   PubMed Web of Science ®Google Scholar
• Addimanda O, Pipitone N, Pazzola G, et al. Tocilizumab for severe refractory neuro-Behcet: three cases IL-6 blockade in neuro-Behcet. Semin Arthritis Rheum 2015;44:472–475
   PubMed Web of Science ®Google Scholar
• Diamantopoulos AP, Hatemi G. Lack of efficacy of tocilizumab in mucocutaneous Behcet's syndrome: report of two cases. Rheumatology (Oxford) 2013;52:1923–1924
   PubMed Web of Science ®Google Scholar
• Shapiro LS, Farrell J, Borhani Haghighi A. Tocilizumab treatment for neuro-Behcet's disease, the first report. Clin Neurol Neurosurg 2012;114:297–298
   PubMed Web of Science ®Google Scholar
• Redondo-Pachon MD, Enríquez R, Sirvent AE, et al. Tocilizumab treatment for nephrotic syndrome due to amyloidosis in Behcet's disease. Ren Fail 2013;35:547–550
   PubMed Web of Science ®Google Scholar
• Cantarini L, Enríquez R, Sirvent AE, et al. Paradoxical mucocutaneous flare in a case of Behçet's disease treated with tocilizumab. Clin Rheumatol 2014
   Web of Science ®Google Scholar
• Shirota Y, Yarboro C, Fischer R, et al. Impact of anti-interleukin-6 receptor blockade on circulating T and B cell subsets in patients with systemic lupus erythematosus. Ann Rheum Dis 2013;72:118–128
   PubMed Web of Science ®Google Scholar
• Ogata A, Tanaka T. Tocilizumab for the treatment of rheumatoid arthritis and other systemic autoimmune diseases: current perspectives and future directions. Int J Rheumatol 2012;2012:946048
   PubMedGoogle Scholar
• Illei GG, Shirota Y, Yarboro CH, et al. Tocilizumab in systemic lupus erythematosus: data on safety, preliminary efficacy, and impact on circulating plasma cells from an open-label phase I dosage-escalation study. Arthritis Rheum 2010;62:542–552
   PubMed Web of Science ®Google Scholar
• Garcia-Hernandez FJ, González-León R, Castillo-Palma MJ, et al. Tocilizumab for treating refractory haemolytic anaemia in a patient with systemic lupus erythematosus. Rheumatology (Oxford) 2012;51:1918–1919
   PubMed Web of Science ®Google Scholar
• Kamata Y, Minota S. Successful treatment of massive intractable pericardial effusion in a patient with systemic lupus erythematosus with tocilizumab. BMJ Case Rep 2012;2012. doi:10.1136/bcr-2012-007834
   Google Scholar
• Makol A, Gibson LE, Michet CJ. Successful use of interleukin 6 antagonist tocilizumab in a patient with refractory cutaneous lupus and urticarial vasculitis. J Clin Rheumatol 2012;18:92–95
   PubMed Web of Science ®Google Scholar
• Gurram M, Pahwa S, Frieri M. Augmented interleukin-6 secretion in collagen-stimulated peripheral blood mo, nonuclear cells from patients with systemic sclerosis. Ann Allergy 1994;73:493–496
   PubMedGoogle Scholar
• Feghali CA, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma. II. Effects of serum and conditioned culture medium on fibroblast function in scleroderma. J Rheumatol 1992;19:1212–1219
   PubMed Web of Science ®Google Scholar
• Sato S, Hasegawa M, Takehara K. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci 2001;27:140–146
   PubMed Web of Science ®Google Scholar
• Shima Y, Kuwahara Y, Murota H, et al. The skin of patients with systemic sclerosis softened during the treatment with anti-IL-6 receptor antibody tocilizumab. Rheumatolgy (Oxford). 2010;49:2408–2412
   PubMed Web of Science ®Google Scholar
• Shima Y, Hosen N, Hirano T, et al. Expansion of range of joint motion following treatment of systemic sclerosis with tocilizumab. Mod Rheumatol 2015;25:134–147
   PubMed Web of Science ®Google Scholar
• Elhai M, Meunier M, Matucci-Cerinic M, et al. Outcomes of patients with systemic sclerosis-associated polyarthritis and myopathy treated with tocilizumab or abatacept: a EUSTAR observational study. Ann Rheum Dis 2013;72:1217–1220
   PubMed Web of Science ®Google Scholar
• McMahan ZH, Wigley FM. Novel investigational agents for the treatment of scleroderma. Expert Opin Investig Drugs 2014;23:183–198
   PubMed Web of Science ®Google Scholar
• Weber E, Gaultier JB, Paul S, et al. Sustained response with tocilizumab in a case of refractory relapsing polychondritis. Rev Med Interne 2014;35:196–198
   PubMed Web of Science ®Google Scholar
• Wendling D, Godfrin-Valnet M, Prati C. Treatment of relapsing polychondritis with tocilizumab. J Rheumatol 2013;40:1232
   PubMed Web of Science ®Google Scholar
• Wallace ZS, Stone JH. Refractory relapsing polychondritis treated with serial success with interleukin 6 receptor blockade. J Rheumatol 2013;40:100–101
   PubMed Web of Science ®Google Scholar
• Stael R, Smith V, Wittoek R, et al. Sustained response to tocilizumab in a patient with relapsing polychondritis with aortic involvement: a case based review. Clin Rheumatol 2015;34:189–193
   PubMed Web of Science ®Google Scholar
• Narshi CB, Allard SA. Sustained response to tocilizumab, anti-IL-6 antibody, following anti-TNF-alpha failure in a patient with relapsing polychondritis complicated by aortitis. Rheumatology (Oxford) 2012;51:952–953
   PubMed Web of Science ®Google Scholar
• Kawai M, Hagihara K, Hiran T, et al. Sustained response to tocilizumab, anti-interleukin-6 receptor antibody, in two patients with refractory relapsing polychondritis. Rheumatology (Oxford) 2009;48:318–319
   PubMed Web of Science ®Google Scholar
• Chen DY, Lan JL, Lin FJ, et al. Proinflammatory cytokine profiles in sera and pathological tissues of patients with active untreated adult onset Still's disease. J Rheumatol 2004;31:2189–2198
   PubMed Web of Science ®Google Scholar
• Ortiz-Sanjuan F, Blanco R, Calvo-Rio V, et al. Efficacy of tocilizumab in conventional treatment-refractory adult-onset Still's disease: multicenter retrospective open-label study of thirty-four patients. Arthritis Rheumatol 2014;66:1659–1665
   PubMed Web of Science ®Google Scholar
• Naniwa T, Ito R, Watanabe M, et al. Case report: successful use of short-term add-on tocilizumab for multirefractory systemic flare of adult-onset Still's disease. Clin Rheumatol 2013;32:103–106
   Web of Science ®Google Scholar
• Perdan-Pirkmajer K, Praprotnik S, Tomsic M. A case of refractory adult-onset Still's disease successfully controlled with tocilizumab and a review of the literature. Clin Rheumatol 2010;29:1465–1467
   PubMed Web of Science ®Google Scholar
• Al-Homood IA. Biologic treatments for adult-onset Still's disease. Rheumatology (Oxford) 2014;53:32–38
   PubMed Web of Science ®Google Scholar
• Silva-Fernandez L, Loza E, Martínez-Taboada VM, et al. Biological therapy for systemic vasculitis: a systematic review. Semin Arthritis Rheum 2014;43:542–557
   PubMed Web of Science ®Google Scholar
• Schafer VS, Zwerina J. Biologic treatment of large-vessel vasculitides. Curr Opin Rheumatol 2012;24:31–37
   PubMed Web of Science ®Google Scholar
• Pazzola G, Padovano I, Boiardi L, et al. Tocilizumab in glucocorticoid-naive large-vessel vasculitis. Clin Exp Rheumatol 2013;31:59–61
   PubMed Web of Science ®Google Scholar
• Clifford A, Hoffman GS. Recent advances in the medical management of Takayasu arteritis: an update on use of biologic therapies. Curr Opin Rheumatol 2014;26:7–15
   PubMed Web of Science ®Google Scholar
• Tombetti E, Franchini S, Papa M, et al. Treatment of refractory Takayasu arteritis with tocilizumab: 7 Italian patients from a single referral center. J Rheumatol 2013;40:2047–2051
   PubMed Web of Science ®Google Scholar
• Nakaoka Y, Higuchi K, Arita Y, et al. Tocilizumab for the treatment of patients with refractory Takayasu arteritis. Int Heart J 2013;54:405–411
   PubMed Web of Science ®Google Scholar
• Abisror N, Mekinian A, Lavigne C, et al. Tocilizumab in refractory Takayasu arteritis: a case series and updated literature review. Autoimmun Rev 2013;12:1143–1149
   PubMed Web of Science ®Google Scholar
• Salvarani C, Magnani L, Catanoso MG, et al. Rescue treatment with tocilizumab for Takayasu arteritis resistant to TNF-alpha blockers. Clin Exp Rheumatol 2012;30:90–93
   PubMed Web of Science ®Google Scholar
• Bredemeier M, Rocha CM, Barbosa MV, et al. One-year clinical and radiological evolution of a patient with refractory Takayasu's arteritis under treatment with tocilizumab. Clin Exp Rheumatol 2012;30:98–100
   PubMed Web of Science ®Google Scholar
• Bravo Mancheño B, Perin F, Guez Vázquez Del Rey Mdel M, et al. Successful tocilizumab treatment in a child with refractory Takayasu arteritis. Pediatrics 2012;130:1720–1724
   PubMed Web of Science ®Google Scholar
• Oliveira F, Butendieck RR, Ginsburg WW, et al. Tocilizumab, an effective treatment for relapsing giant cell arteritis. Clin Exp Rheumatol 2014;32:76–78
   Google Scholar
• Kieffer P, Hinschberger O, Ciobanu E, et al. Clinical and biological efficacy of tocilizumab in giant cell arteritis: report of three patients and literature review. Rev Med Interne 2014;35:56–59
   PubMed Web of Science ®Google Scholar
• Isik M, Kılıç L, Doğan İ, et al. Tocilizumab for giant cell arteritis: an amazing result. Rheumatol Int 2013;33:2961–2962
   PubMed Web of Science ®Google Scholar
• Lurati A, Bertani L, Re KA, et al. Successful treatment of a patient with giant cell vasculitis (horton arteritis): with tocilizumab a humanized anti-interleukin-6 receptor antibody. Case Rep Rheumatol 2012;2012:639612
   PubMedGoogle Scholar
• Besada E, Nossent JC. Ultrasonographic resolution of the vessel wall oedema with modest clinical improvement in a large-vessel vasculitis patient treated with tocilizumab. Clin Rheumatol 2012;31:1263–1265
   PubMed Web of Science ®Google Scholar
• Cohen C, Mekinian A, Saidenberg-Kermanac'h N, et al. Efficacy of tocilizumab in rituximab-refractory cryoglobulinemia vasculitis. Ann Rheum Dis 2012;71:628–629
   PubMed Web of Science ®Google Scholar
• Sumida K, Ubara Y, Takemoto F, et al. Successful treatment with humanised anti-interleukin 6 receptor antibody for multidrug-refractory and anti-tumour necrosis factor-resistant systemic rheumatoid vasculitis. Clin Exp Rheumatol 2011;29:S133
   PubMed Web of Science ®Google Scholar
• Tawara I, Koyama M, Liu C, et al. Interleukin-6 modulates graft-versus-host responses after experimental allogeneic bone marrow transplantation. Clin Cancer Res 2011;17:77–88
   PubMed Web of Science ®Google Scholar
• Drobyski WR, Pasquini M, Kovatovic K, et al. Tocilizumab for the treatment of steroid refractory graft-versus-host disease. Biol Blood Marrow Transplant 2011;17:1862–1868
   PubMed Web of Science ®Google Scholar
• Kolb M, Bhatia M, Madina GG, et al. Effective use of tocilizumab for the treatment of steroid-refractory gastrointestinal acute graft versus host disease in a child with very high levels of serum interleukin-6. Pediatr Blood Cancer 2014. doi: 10.1002/pbc.25231
   Web of Science ®Google Scholar
• Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011;128:1128–1130
   PubMed Web of Science ®Google Scholar
• Kondo M, Murakawa Y, Matsumura T, et al. A case of overlap syndrome successfully treated with tocilizumab: a hopeful treatment strategy for refractory dermatomyositis? .Rheumatology (Oxford) 2014;53:1907–1908
   PubMed Web of Science ®Google Scholar
• Campbell L, Chen C, Bhagat SS, et al. Risk of adverse events including serious infections in rheumatoid arthritis patients treated with tocilizumab: a systematic literature review and meta-analysis of randomized controlled trials. Rheumatology (Oxford) 2011;50:552–562
   PubMed Web of Science ®Google Scholar
• Bracarda S, Porta C, Sisani M, et al. Comparing comparators: a look at control arms in kidney cancer studies over the years. Br J Cancer 2014;112:14--19
   PubMed Web of Science ®Google Scholar
• Kubandova Z, Porta C, Sisani M, et al. Serious herpes zoster in rheumatoid arthritis under anti-interleukin-6 receptor antibody. Joint Bone Spine 2010;77:623–624
   PubMed Web of Science ®Google Scholar
• Ikegawa K, Hanaoka M, Ushiki A, et al. A case of organizing pneumonia induced by tocilizumab. Intern Med 2011;50:2191–2193
   PubMed Web of Science ®Google Scholar
• Van Duin D, Miranda C, Husni E. Cytomegalovirus viremia, pneumonitis, and tocilizumab therapy. Emerg Infect Dis 2011;17:754–756
   PubMed Web of Science ®Google Scholar
• de Kruif MD, van Gorp EC, Bel EH, et al. Streptococcal lung abscesses from a dental focus following tocilizumab: a case report. Clin Exp Rheumatol 2012;30:951–953
   PubMed Web of Science ®Google Scholar
• Hoshi D, Nakajima A, Inoue E, et al. Incidence of serious respiratory infections in patients with rheumatoid arthritis treated with tocilizumab. Mod Rheumatol 2012;22:122–127
   PubMed Web of Science ®Google Scholar
• Milin M, Acquitter M, Le Berre R, et al. Bartonella henselae infection during tocilizumab therapy. Joint Bone Spine 2013;80:221
   PubMed Web of Science ®Google Scholar
• Guyen MT, Podenphant J, Ravn P. Three cases of severely disseminated Staphylococcus aureus infection in patients treated with tocilizumab. BMJ Case Rep 2013. doi: 10.1136/bcr-2012-007413
   Google Scholar
• Honda H, Kida H, Yoshida M, et al. Recurrent allergic bronchopulmonary aspergillosis in a patient with rheumatoid arthritis treated with etanercept and tocilizumab. Mod Rheumatol 2011;21:660–664
   PubMed Web of Science ®Google Scholar
• Tocilizumab: intestinal perforations. Prescrire Int 2010;19:216
   Google Scholar
• Gout T, Ostor AJ, Nisar MK. Lower gastrointestinal perforation in rheumatoid arthritis patients treated with conventional DMARDs or tocilizumab: a systematic literature review. Clin Rheumatol 2011;30:1471–1474
   PubMed Web of Science ®Google Scholar
• Iwasa T, Nakamura K, Ogino H, et al. Multiple ulcers in the small and large intestines occurred during tocilizumab therapy for rheumatoid arthritis. Endoscopy 2011;43:70–72
   PubMed Web of Science ®Google Scholar
• Alfreijat M, Habibi M, Bhatia P, et al. Severe hepatitis associated with tocilizumab in a patient with rheumatoid arthritis. Rheumatology (Oxford) 2013;52:1340–1341
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Ito K, Takagi N. Safety and efficacy profiles of tocilizumab mo, notherapy in Japanese patients with rheumatoid arthritis: meta-analysis of six initial trials and five long-term extensions. Mod Rheumatol 2010;20:222–232
   PubMed Web of Science ®Google Scholar
• Nagamine R, Chen W, Hara T, et al. Immediate reduction of white blood cell count after tocilizumab administration was observed in some cases. Mod Rheumatol 2009;19:348–350
   PubMed Web of Science ®Google Scholar
• Genovese MC, Rubbert-Roth A, Smolen JS, et al. Longterm safety and efficacy of tocilizumab in patients with rheumatoid arthritis: a cumulative analysis of up to 4.6 years of exposure. J Rheumatol 2013;40:768–780
   PubMed Web of Science ®Google Scholar
• Schiff MH, Kremer JM, Jahreis A, et al. Integrated safety in tocilizumab clinical trials. Arthritis Res Ther 2011;13:R141
   PubMed Web of Science ®Google Scholar
• Pham T, Claudepierre P, Constantin A, et al. Tocilizumab: therapy and safety management. Joint Bone Spine 2010;77:S3–S100
   PubMed Web of Science ®Google Scholar
• Emery P, Keystone E, Tony HP, et al. IL-6 receptor inhibition with tocilizumab improves treatment outcomes in patients with rheumatoid arthritis refractory to anti-tumour necrosis factor biologicals: results from a 24-week multicentre randomised placebo-controlled trial. Ann Rheum Dis 2008;67:1516–1523
   PubMed Web of Science ®Google Scholar
• Jones G. The AMBITION trial: tocilizumab monotherapy for rheumatoid arthritis. Expert Rev Clin Immunol 2010;6:189–195
   PubMed Web of Science ®Google Scholar
• Finet A, Amini-Adle M, Balme B, et al. Nodular progression of lentigo malignant melanoma during a treatment with tocilizumab: cause or coincidence? Clin Rheumatol 2013;32:277–280
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Miyasaka N, Yamamoto K, et al. Long-term safety and efficacy of tocilizumab, an anti-IL-6 receptor mo, noclonal antibody, in monotherapy, in patients with rheumatoid arthritis, (the STREAM study): evidence of safety and efficacy in a 5-year extension study. Ann Rheum Dis 2009;68:1580–1584
   PubMed Web of Science ®Google Scholar
• Oldfield V, Dhillon S, Plosker GL. Tocilizumab: a review of its use in the management of rheumatoid arthritis. Drugs 2009;69:609–632
   PubMed Web of Science ®Google Scholar
• Rocchi V, Puxeddu I, Cataldo G, et al. Hypersensitivity reactions to tocilizumab: role of skin tests in diagnosis. Rheumatology (Oxford) 2014;53:1527–1529
   PubMed Web of Science ®Google Scholar
• Yamanaka H, Tanaka Y, Inoue E, et al. Efficacy and tolerability of tocilizumab in rheumatoid arthritis patients seen in daily clinical practice in Japan: results from a retrospective study, (REACTION study). Mod Rheumatol 2011;21:122–133
   PubMed Web of Science ®Google Scholar
• Ohta S, Tsuru T, Terao K, et al. Mechanism-based approach using a biomarker response to evaluate tocilizumab subcutaneous injection in patients with rheumatoid arthritis with an inadequate response to synthetic DMARDs, (MATSURI study). J Clin Pharmacol 2014;54:109–119
   PubMed Web of Science ®Google Scholar
• Imagawa T, Yokota S, Mori M, et al. Safety and efficacy of tocilizumab, an anti-IL-6-receptor mo, noclonal antibody, in patients with polyarticular-course juvenile idiopathic arthritis. Mod Rheumatol 2012;22:109–115
   PubMed Web of Science ®Google Scholar
• Dougados M, Kissel K, Conaghan PG, et al. Clinical, radiographic and immu, nogenic effects after 1 year of tocilizumab-based treatment strategies in rheumatoid arthritis: the ACT-RAY study. Ann Rheum Dis 2014;73:803–809
   PubMed Web of Science ®Google Scholar
• Bannwarth B, Richez C. Clinical safety of tocilizumab in rheumatoid arthritis. Expert Opin Drug Saf 2011;10:123–131
   PubMed Web of Science ®Google Scholar
• Kim S, Ostor AJ, Nisar MK. Interleukin-6 and cytochrome-P450, reason for concern? Rheumatol Int 2012;32:2601–2604
   PubMed Web of Science ®Google Scholar
• Hyrich KL, Verstappen SM. Biologic therapies and pregnancy: the story so far. Rheumatology (Oxford) 2014;53:1377–1385
   PubMed Web of Science ®Google Scholar